Screener
Liquidia Corporation LQDA Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Program Expenses by Product | ||||||
| Generic Treprostinil | $9K-92.8% | -$49K-132% | $67K-46.0% | $21K-86.2% | $125K-48.1% | |
| L606 | $10.78M+286% | $5.82M+78.2% | $10.42M+46.2% | $3.2M+89.0% | $2.79M+68.6% | |
| Yutrepia | $19.33M+31.8% | $15.89M+62.8% | $15.54M-15.4% | $15.49M+94.3% | $14.66M+234% |
FAQ
- How does Liquidia Corporation break its business down?
- Liquidia Corporation (LQDA) reports program expenses by product across 3 parts — Generic Treprostinil, L606 and Yutrepia. Each is extracted from the segment footnotes and tracked over time.
- Where does Liquidia Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Liquidia Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
